Editing Medical therapy for obesity (section)

== '''Drug options''' ==

* '''Incretin-based     therapies''' (GLP-1     and GIP, essentially; gut hormones that respond to nutrient intake)
** '''GLP-1      agonists'''
*** Semaglutide (Ozempic in low       dose, Wegovy in high dose)
**** As of March 2025, only on        PBS for T2DM, and recommended not to use off-label due to global        shortages
**** Weekly subcutaneous        injection
**** GIT side effects - delayed        gastric emptying, gastritis, abdominal pain
**** Particularly good for        diabetics
**** Need to continue for over        a year for best results
**** Weight will go back on        after stopping, but not straight away
*** Liraglutide
**** Daily subcutaneous        injection
** '''GIP      agonists'''
*** Tirzepatide (Mounjaro) -       GIP and GLP-1 agonist
*** Theoretically better, but       not tested head-to-head yet
** Contraindications:
*** Personal or family history       of medullary thyroid cancer of MEN2 - possible increased risk
*** Pregnancy
** Adverse effects:
*** Nausea 25-40%
*** Vomiting, diarrhoea or       constipation 10-20%
*** Gastroparesis
*** Pancreatitis (likely just       microlithiasis)
** Strategies to mitigate      risks:
*** Smaller, more frequent       meals
*** Eating slowly
*** Limiting fatty meals
* Old options
** Phentermine +      extended-release topiramate
** Bupropion-naltrexone
** Orlistat
** Phentermine



[[Category:Bariatrics]]